Pfizer’s Xeljanz XR (tofacitinib) Receives the US FDA’s Approval for Ulcerative Colitis

 Pfizer’s Xeljanz XR (tofacitinib) Receives the US FDA’s Approval for Ulcerative Colitis

Pfizer’s Xeljanz XR (tofacitinib) Receives the US FDA’s Pfizer’s Xeljanz XR (tofacitinib) Receives the US FDA’s Approval for Ulcerative Colitis Approval for Ulcerative Colitis

Shots:

  • The US FDA has approved Xeljanz XR extended-release (11 & 22mg, qd) for the treatment of mod. to sev. active UC, after an inadequate response or intolerance to TNF blockers
  • Pfizer will advance the science of JAK inhibition and enhance the understanding of Xeljanz XR via robust clinical development programs in the treatment of immune-mediated inflammatory conditions
  • Xeljanz XR (qd) is the first and only JAK inhibitor, which allows patients living with mod. to sev. active UC to manage their disease and has received approval in 130+ countries for moderately to severely active RA, UC, and PsA

Click here to­ read full press release/ article | Ref: Pfizer | Image: Behance

Leave a Reply

Your email address will not be published. Required fields are marked *